Gleevec For What? Imatinib NDA For PAH Will Face Safety Questions At Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis said there was a higher rate of unspecified serious adverse events in the active arm of the pivotal trial for pulmonary arterial hypertension.
You may also be interested in...
PAH Market Snapshot: Actelion’s Tracleer Faces Stiffer U.S. Competition
United Therapeutics' recently approved pulmonary arterial hypertension drug Adcirca threatens to close in on the vast lead held by Actelion's Tracleer, though surpassing the market pioneer seems nearly impossible. Not to mention, the Swiss-based biotech has an ace up its sleeve with the expansive REVEAL patient registry
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Ranbaxy’s Atorvastatin Recall: Will Glass Shards Nick FDA’s Reputation?
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.